Last reviewed · How we verify
Symbicort TBH - Turbuhaler
Symbicort TBH is a combination of budesonide and formoterol, a corticosteroid and a long-acting beta2-adrenergic receptor agonist, respectively, used to control symptoms of asthma and COPD.
Symbicort TBH is a combination of budesonide and formoterol, a corticosteroid and a long-acting beta2-adrenergic receptor agonist, respectively, used to control symptoms of asthma and COPD. Used for Maintenance and relief of asthma symptoms, Maintenance and relief of symptoms in COPD.
At a glance
| Generic name | Symbicort TBH - Turbuhaler |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Corticosteroid and long-acting beta2-adrenergic receptor agonist combination |
| Target | Beta2-adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Budesonide is a corticosteroid that reduces inflammation in the airways, while formoterol is a long-acting beta2-adrenergic receptor agonist that relaxes bronchial muscles, making it easier to breathe. The combination of these two medications provides sustained relief from asthma and COPD symptoms.
Approved indications
- Maintenance and relief of asthma symptoms
- Maintenance and relief of symptoms in COPD
Common side effects
- Oral candidiasis
- Headache
- Pharyngitis
- Cough
- Dysphonia
Key clinical trials
- A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS) (PHASE3)
- A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos) (PHASE3)
- Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD (PHASE3)
- A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma (PHASE3)
- A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Symbicort TBH - Turbuhaler CI brief — competitive landscape report
- Symbicort TBH - Turbuhaler updates RSS · CI watch RSS
- AstraZeneca portfolio CI